Literature DB >> 20700098

Differential diagnosis and overlap of acute chest discomfort and dyspnea in the emergency department.

Norman E Lepor1, Peter A McCullough.   

Abstract

Acute chest discomfort and dyspnea are 2 of the most common nontraumatic symptoms that prompt emergency department evaluations in the United States. The overlap between these presenting symptoms is considerable. In addition, each symptom calls for a broad differential diagnosis that requires rapid refinement according to details in the history, physical examination, blood biomarkers, and radiographic evaluation. This article highlights the epidemiology and the evidence supporting critical decision making, which makes judicious use of the clinical laboratory and diagnostic radiology in the evaluation of the acutely ill patient with chest discomfort and dyspnea.

Entities:  

Mesh:

Year:  2010        PMID: 20700098     DOI: 10.3909/ricm11S2S0006

Source DB:  PubMed          Journal:  Rev Cardiovasc Med        ISSN: 1530-6550            Impact factor:   2.930


  3 in total

1.  Interpretation of positive troponin results among patients with and without myocardial infarction.

Authors:  Kristen M Tecson; William Arnold; Tyler Barrett; Robert Birkhahn; Lori B Daniels; Christopher DeFilippi; Gary Headden; W Frank Peacock; Michael Reed; Adam J Singer; Jeffrey M Schussler; Stephen Smith; Martin P Than; Peter A McCullough
Journal:  Proc (Bayl Univ Med Cent)       Date:  2017-01

2.  SEARCH 8Es: A novel point of care ultrasound protocol for patients with chest pain, dyspnea or symptomatic hypotension in the emergency department.

Authors:  Jung Hwan Ahn; Jin Jeon; Hong-Chuen Toh; Vicki Elizabeth Noble; Jun Su Kim; Young Sik Kim; Han Ho Do; Young Rock Ha
Journal:  PLoS One       Date:  2017-03-29       Impact factor: 3.240

3.  Shifting up cutoff value of d-dimer in the evaluation of pulmonary embolism: a viable option? Possible risks and benefits.

Authors:  Bennidor Raviv; Shlomo H Israelit
Journal:  Emerg Med Int       Date:  2012-07-24       Impact factor: 1.112

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.